IL226449A0 - A complex formulation containing larcanidipin - Google Patents

A complex formulation containing larcanidipin

Info

Publication number
IL226449A0
IL226449A0 IL226449A IL22644913A IL226449A0 IL 226449 A0 IL226449 A0 IL 226449A0 IL 226449 A IL226449 A IL 226449A IL 22644913 A IL22644913 A IL 22644913A IL 226449 A0 IL226449 A0 IL 226449A0
Authority
IL
Israel
Prior art keywords
valsartan
preparation
lercanidipine hydrochloride
complex formulation
formulation
Prior art date
Application number
IL226449A
Other languages
English (en)
Hebrew (he)
Original Assignee
Lg Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46207595&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL226449(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lg Life Sciences Ltd filed Critical Lg Life Sciences Ltd
Publication of IL226449A0 publication Critical patent/IL226449A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
IL226449A 2010-12-09 2013-05-20 A complex formulation containing larcanidipin IL226449A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20100125804 2010-12-09
PCT/KR2011/009413 WO2012077968A2 (en) 2010-12-09 2011-12-07 Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof

Publications (1)

Publication Number Publication Date
IL226449A0 true IL226449A0 (en) 2013-07-31

Family

ID=46207595

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226449A IL226449A0 (en) 2010-12-09 2013-05-20 A complex formulation containing larcanidipin

Country Status (17)

Country Link
EP (1) EP2648730A4 (ko)
KR (1) KR101414814B1 (ko)
CN (1) CN103249415B (ko)
AR (1) AR084195A1 (ko)
AU (1) AU2011339150B2 (ko)
BR (1) BR112013013415A2 (ko)
CL (1) CL2013001626A1 (ko)
CO (1) CO6721030A2 (ko)
DO (1) DOP2013000115A (ko)
EA (1) EA201390844A1 (ko)
IL (1) IL226449A0 (ko)
MX (1) MX2013005716A (ko)
PE (1) PE20140699A1 (ko)
SG (1) SG190326A1 (ko)
UA (1) UA108277C2 (ko)
UY (1) UY33772A (ko)
WO (1) WO2012077968A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
AU2014230304B2 (en) * 2013-03-12 2018-07-05 Lg Chem, Ltd. Complex preparation including valsartan and rosuvastatin calcium and manufacturing method therefor
WO2019008485A1 (en) 2017-07-06 2019-01-10 Mankind Pharma Ltd FIXED DOSE PHARMACEUTICAL COMPOSITION BASED ON VALSARTAN AND SACUBITRIL
KR102233986B1 (ko) * 2019-06-25 2021-03-30 경남과학기술대학교 산학협력단 라푸티딘 및 이르소글라딘을 함유하는 고형 약제학적 조성물 및 이의 제조방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
EA013426B1 (ru) * 2003-12-01 2010-04-30 Рекордати Айэлэнд Лимитед Фармацевтические композиции, содержащие лерканидипин
WO2007001067A2 (en) * 2005-06-27 2007-01-04 Daiichi Sankyo Company, Limited Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker
KR100888131B1 (ko) * 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제

Also Published As

Publication number Publication date
PE20140699A1 (es) 2014-06-13
UY33772A (es) 2012-07-31
CN103249415B (zh) 2017-12-12
EP2648730A2 (en) 2013-10-16
AU2011339150B2 (en) 2015-09-10
WO2012077968A2 (en) 2012-06-14
EP2648730A4 (en) 2014-08-06
AU2011339150A1 (en) 2013-06-06
WO2012077968A3 (en) 2012-07-26
EA201390844A1 (ru) 2013-11-29
BR112013013415A2 (pt) 2019-09-24
UA108277C2 (ru) 2015-04-10
CN103249415A (zh) 2013-08-14
AR084195A1 (es) 2013-04-24
SG190326A1 (en) 2013-06-28
MX2013005716A (es) 2013-06-12
CL2013001626A1 (es) 2013-10-04
CO6721030A2 (es) 2013-07-31
KR20120089787A (ko) 2012-08-13
DOP2013000115A (es) 2014-07-31
KR101414814B1 (ko) 2014-07-21

Similar Documents

Publication Publication Date Title
IL269804A (en) Conjugates of an active protein material and a method for their preparation
GB2477588B (en) Self-making bread method, bread machine and bread ingredient box thereof
GB201116610D0 (en) A copolymer and preparation method and application thereof
EP2657188A4 (en) FLUOROGRAPHIC AND METHOD FOR PREPARING THE SAME
EP2578584A4 (en) ARYLAMINE DERIVATIVES OF PURINE, PROCESS FOR PREPARING THEM AND THEIR PHARMACEUTICAL USE
IL216171A (en) Lipidic Compound, Method for Preparing the Compound, Pharmaceutical and Lipid Preparations Containing Their Composition and Uses
EP2603546A4 (en) POLYSILOXANE-POLYLACTIC BLOCK COPOLYMER AND PROCESS FOR PREPARING THE SAME
EP2551258A4 (en) SUBSTITUTED DIPHENYLAMINE COMPOUNDS, PREPARATION METHOD AND USE THEREOF
AP3222A (en) Germination-stimulant carbamate derivatives and process for preparation thereof
EP2573072A4 (en) INDENOQUINOLONE COMPOUND, PROCESS FOR PREPARING THE SAME, AND USE THEREOF
EP2607076A4 (en) PERSPECTIVE FILM AND MANUFACTURING METHOD THEREFOR
ZA201400188B (en) Substituted cinnamamide derivative, preparation method and use thereof
EP2786982A4 (en) AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF
EP2924042A4 (en) BIS-BETA-CARBOLINE COMPOUND AND METHOD OF MANUFACTURING, PHARMACEUTICAL COMPOSITION AND USE THEREOF
AP2013006842A0 (en) Lubricating composition and method for the preparation thereof
EP2781512A4 (en) OXADIAZOLE COMPOUND AND PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF
ZA201206740B (en) Aildenafil citrate crystal form o,preparation method and use thereof
IL226449A0 (en) A complex formulation containing larcanidipin
EP2636675A4 (en) DIPHOSPHONATE COMPOUNDS AND PROCESS FOR THE PREPARATION AND USE THEREOF
EP2837380A4 (en) LERCANIDIPINHYDROCHLORIDE AND CALIUM LOSARTAN COMBINATION PREPARATION AND MANUFACTURING METHOD THEREFOR
EP2634184A4 (en) C-ARYLGLUCOSIDE DERIVATIVE, PREPARATION METHOD AND USE THEREOF
HK1186185A1 (zh) 咪唑衍生物、製備方法及用途
EP2617293A4 (en) INGREDIENT MASKING AMERTUME AND METHOD OF MASKING AMERTUME
EP2565180A4 (en) ALPHA-ARYLMETHOXYACRYLATE DERIVATIVE PRODUCTION METHOD AND PHARMACEUTICAL COMPOSITION THEREWITH
PL2736496T3 (pl) Kompozycja farmaceutyczna zawierająca środek przeciwmuskarynowy i sposób jej wytwarzania